Oils from marine samples are known to contain high concentrations of arsenolipids. However, their identification in lipid matrix poses a significant challenge especially when present in low concentrations. Here, we report the identification of sixteen arsenolipids in cod-liver oil. The fish oil was fractionated on a silica gel column and the fraction enriched with arsenic analysed using RP-HPLC online with ICP-MS and ES-Orbitrap-MS. Among the arsenolipids identified nine compounds have not been reported before. Structural assignment was achieved by arsenic signal from ICP-MS, retention time behaviour and accurate mass determination of fragment and molecular peaks. In addition, the unknown degradation products of arsenolipids eluting in the void volume were investigated using fraction collection, cation exchange chromatography and accurate mass determination, and were found to contain predominantly dimethylarsinic acid (DMA) with trace amounts of methylarsonic acid (MA), dimethylarsenopropanoic acid (DMAP) and dimethylarsenobutanoic acid (DMAB). This finding is essential in epidemiologic studies where urinary DMA and other arsenic metabolites have been used as biomarker in accessing human exposure to arsenic.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.talanta.2013.09.056 | DOI Listing |
Microbiome
January 2025
Department of Microbiome Dynamics, Leibniz Institute for Natural Product Research and Infection Biology - Hans Knöll Institute, Beutenbergstraße 11A, Jena, 07745, Germany.
Background: The pathogenesis of non-alcoholic fatty liver disease (NAFLD) with a global prevalence of 30% is multifactorial and the involvement of gut bacteria has been recently proposed. However, finding robust bacterial signatures of NAFLD has been a great challenge, mainly due to its co-occurrence with other metabolic diseases.
Results: Here, we collected public metagenomic data and integrated the taxonomy profiles with in silico generated community metabolic outputs, and detailed clinical data, of 1206 Chinese subjects w/wo metabolic diseases, including NAFLD (obese and lean), obesity, T2D, hypertension, and atherosclerosis.
Crit Care
January 2025
Department of Anesthesiology and Critical Care Medicine, Yokohama City University School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa, 236-0004, Japan.
Background: Both quantitative and qualitative aspects of muscle status significantly impact clinical outcomes in critically ill patients. Comprehensive monitoring of baseline muscle status and its changes is crucial for risk stratification and management optimization. However, repeatable and accessible indicators are lacking.
View Article and Find Full Text PDFGenome Biol
January 2025
The Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Kongens Lyngby, 2800, Denmark.
Background: Streptomyces is a highly diverse genus known for the production of secondary or specialized metabolites with a wide range of applications in the medical and agricultural industries. Several thousand complete or nearly complete Streptomyces genome sequences are now available, affording the opportunity to deeply investigate the biosynthetic potential within these organisms and to advance natural product discovery initiatives.
Results: We perform pangenome analysis on 2371 Streptomyces genomes, including approximately 1200 complete assemblies.
World J Surg Oncol
January 2025
Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Early-onset (EOCC) and late-onset cervical cancers (LOCC) represent two clinically distinct subtypes, each defined by unique clinical manifestations and therapeutic responses. However, their immunological profiles remain poorly explored. Herein, we analyzed single-cell transcriptomic data from 4 EOCC and 4 LOCC samples to compare their immune architectures.
View Article and Find Full Text PDFMicrob Cell Fact
January 2025
Botany Department, Faculty of Science, Tanta University, Tanta, 31527, Egypt.
Extensive anthropogenic activity has led to the accumulation of organic and inorganic contaminants in diverse ecosystems, which presents significant challenges for the environment and its inhabitants. Utilizing microalgae as a bioremediation tool can present a potential solution to these challenges. Microalgae have gained significant attention as a promising biotechnological solution for detoxifying environmental pollutants.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!